Keystonemab
Even though 90% of all clinical research for new medicine ends in a failure, these studies do gather useful data. They offer a solution while developing other medicine. Perhaps a rejected drug can successfully be used for another treatment, or to boost the effectiveness of other medicine. The problem: there are numerous scientific data. Combing through…
Developing a new drug requires a lot of investment in time, money and human resources. The procedure involves a clinical trial, as well as a test phase. Of course, the new medicine needs the approval from the authorities as well. By tapping the potential of Artificial Intelligence (AI), this process can be sped up considerably.…
Press Release: Sept. 30, 2022 – Utrecht, the Netherlands We are delighted to welcome Nitin as a seed investor and Chief Corporate Development Officer of Keystonemab. Nitin will actively help with developing Keystonemab’s corporate strategy and business relationships in high growth market including India. Nitin is a serial entrepreneur with focus on industrial real-estate since…
